Clinical management of spasticity

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 76, Issue 4, 2005, Pages 459-463

  Thompson, Alon J ^a,b   Jarrett, L ^a   Lockley, L ^a   Marsden, J ^b   Stevenson, V L ^a  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID RECEPTOR; ACETYLCHOLINE; BACLOFEN; BENZODIAZEPINE; BOTULINUM TOXIN; DANTROLENE; GABAPENTIN; PHENOL; TIZANIDINE;

ALGORITHM; DISABILITY; DISEASE SEVERITY; DROWSINESS; EDITORIAL; HUMAN; MULTIPLE SCLEROSIS; MUSCLE STRETCHING; MUSCLE WEAKNESS; NEUROLOGIC DISEASE; NURSING; PATIENT MONITORING; PHYSIOTHERAPY; PRIORITY JOURNAL; SPASTICITY; SPLINT; TREATMENT PLANNING;

ALGORITHMS; BOTULINUM TOXIN TYPE A; CEREBRAL PALSY; ELECTRIC STIMULATION THERAPY; FECAL INCONTINENCE; HUMANS; MOTOR NEURONS; MOVEMENT DISORDERS; NEURAL INHIBITION; NEUROMUSCULAR AGENTS; PATIENT CARE TEAM; PHYSICAL THERAPY MODALITIES; SEVERITY OF ILLNESS INDEX; URINARY BLADDER DISEASES;

EID: 16844385387     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.2004.035972     Document Type: Editorial

References (32)

1. Brown P. The pathophysiology of spasticity. J Neurol Neurosurg Psychiatry 1991;238:131-9.
2. Burke D. Spasticity as an adaptation to pyramidal tract injury. Adv Neurol 1988;47:401-23.
3. Wilson LR, Gandevia SC, Inglis JT, et al. Muscle spindle activity in the affected upper limb after a unilatreral stroke. Brain 1999;122:2079-88.
4. Aymard C, Katz R, Lafitte C, et al. Presynaptic inhibition and homosynaptic depression. A comparison between lower and uppper limbs in normal human subjects and patients with hemiplegia. Brain 2000;123:1688-702.
5. Zijdewind I, Thomas CK. Spontaneous motor unit behavior in human thenar muscles after spinal cord injury. Muscle Nerve 2001;24:952-62.
6. Zijdewind I, Thomas CK. Motor unit firing during and after voluntary contractions of human thenar muscles weakened by spinal cord injury. J Neurophysiol 2003;89:2065-71.
7. Bennett DJ, Li Y, Harvey PJ, et al. Evidence for plateau potentials in tail motoneurons of awake chronic spinal rats with spasticity. J Neurophysiol 2001;86:1972-82.
8. Nickolls P, Collins DF, Gorman RB, et al. Forces consistent with plateau-like behaviour of spinal neurons evoked in patients with spinal cord injuries. Brain 2004;127:660-70.
9. Dietz V. Spastic movement disorder: what is the impact of research on clinical practice? J Neurol Neurosurg Psychiatry 2003;74:820-6.
10. Dewald JP, Pope PS, Given JD, et al. Abnormal muscle coactivation patterns during isometric torque generation at the elbow and shoulder in hemiparetic subjects. Brain 1995;118:495-510.
11. Canning CG, Ada L, O'Dwyer NJ. Abnormal muscle activation characteristics associated with loss of dexterity after stroke. J Neurol Sci 2000;176:45-56.
12. Schmit BD, Benz EN, Rymer WZ. Reflex mechanisms for motor impairment in spinal cord injury. Adv Exp Med Biol 2002;508:315-23.
13. Norton JA, Marsden JF, Day BL. Spinally generated electromyographic oscillations and spasms in a low-thoracic complete paraplegic. Mov Disord 2003;18:101-6.
14. Richardson D, Thompson AJ. Management of spasticity in hereditary spastic paraplegia. Physiother Res Int 1999;4:68-76.
15. Jarrett L. The role of the nurse in the management of spasticity. Nurs Resident Care 2004;3:116-19.
16. Koman LA, Smith BP, Shilt JS. Cerebral palsy. Lancet 2004;363:1619-31.
17. Richardson D. Physical therapy in spasticity. Eur J Neurol 2002;9:17-22.
18. Burridge J, Taylor P, Hagan S, et al. The effects of common peroneal stimulation on the effort and speed of walking: a randomised controlled clinical trial with chronic hemiplegic patients. Clin Rehabil 1997;11:201-10.
19. Davis EC, Barnes MP. Botulinum toxin and spasticity. J Neurol Neurosurg Psychiatry 2000;69:143-9.
20. Richardson D, Sheean G, Werring D, et al. Evaluating the role of botulinum toxin in the management of focal hypertonia in adults. J Neurol Neurosurg Psychiatry 2000;69:499-506.
21. Brashear A, Gordon MF, Elovic E, et al. Botox Post-Stroke Spasticity Study Group. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med 2002;347:395-400.
22. Sheean GL. Botulinum treatment of spasticity: why is it so difficult to show a functional benefit? Curr Opin Neurol 2001;14:771-6.
23. Barnes MP. Local treatment of Spasticity. Baillieres Clin Neurol 1993;2:55-71.
24. Beard S, Hunn A, Wright J. Treatments for spasticity and pain in multiple sclerosis: a systematic review. Health Technol Assess 2003;7:1-111.
25. Jarrett L, Nandi P, Thompson AJ. Managing severe lower limb spasticity in multiple sclerosis: does intrathecal phenol have a role? J Neurol Neurosurg Psychiatry 2002;73:705-9.
26. Ashworth B. Preliminary trial of carisoprodal in multiple sclerosis. Practitioner 1964;192:540-2.
27. Hobart J. Rating scales for neurologists. J Neurol Neurosurg Psychiatry 2003;74(suppl IV):iv705-9.
28. Pomeroy VM, Dean D, Sykes L, et al. The unreliability of clinical measures of muscle tone: the implications for stroke therapy. Age Ageing 2000;29:229-33.
29. Riazi A, Fox P, Vickery J, et al. Developing a patient-based measure of the impact of spasticity in multiple sclerosis. Multiple Sclerosis 2003;9:S151.
30. Priebe MM, Sherwood AM, Thornby JI, et al. Clinical assessment of spasticity in spinal cord injury: a multidimensional problem. Arch Phys Med Rehabil 1996;77:713-16.
31. Johnson GR. Outcome measures of spasticity. Eur J Neurol 2002;9(suppl 1):10-16.
32. Multiple Sclerosis Council for Clinical Practice Guidelines. Spasticity management in multiple sclerosis: evidence Based management strategies for spasticity treatment in multiple sclerosis. Paralyzed Veterans of America/Consortium of Multiple Sclerosis Centres, 2003:27pp.